Gilternib 40 mg, containing the active ingredient Gilteritinib, is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) harboring a FMS-like tyrosine kinase 3 (FLT3) mutation, as confirmed by an FDA-approved test. This targeted therapy is particularly suitable for patients who have limited treatment options due to prior therapy failure, offering a precision approach by directly inhibiting the abnormal signaling pathways that drive leukemia cell proliferation.

Description

Gilternib 40 mg is an oral small-molecule inhibitor designed to target FLT3, a receptor tyrosine kinase frequently mutated in AML. FLT3 mutations, including internal tandem duplications (ITD) and tyrosine kinase domain (TKD) mutations, are associated with aggressive disease progression and poor prognosis. By selectively inhibiting these mutated FLT3 receptors, Gilternib blocks downstream signaling pathways that promote leukemic cell survival and proliferation, thereby helping to control disease progression and induce remission.

Pharmacology

Gilteritinib acts as a potent, selective inhibitor of multiple receptor tyrosine kinases, with strong activity against FLT3. In preclinical studies, it has demonstrated the ability to inhibit both FLT3-ITD and FLT3-TKD mutations, leading to reduced proliferation and increased apoptosis of leukemia cells. Its mechanism also indirectly disrupts signaling through pathways such as STAT5, MAPK, and PI3K/AKT, which are critical for leukemic cell survival. Gilteritinib is metabolized primarily in the liver, mainly via CYP3A4, and exhibits a half-life conducive to once-daily oral administration, ensuring sustained FLT3 inhibition with manageable dosing.

Dosage & Administration

Gilternib 40 mg is administered orally, once daily, with or without food. The recommended dose for adults is 120 mg once daily, which may be adjusted based on tolerability and hepatic function. Dose adjustments are necessary for patients with moderate to severe hepatic impairment or those taking strong CYP3A4 inhibitors or inducers, as drug interactions can alter plasma concentrations. Regular monitoring of complete blood counts and liver function tests is recommended during therapy to ensure safety and efficacy.

Interaction

Gilteritinib may interact with CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) and CYP3A4 inducers (e.g., rifampicin, phenytoin), which can increase or decrease drug exposure, respectively. Concomitant use of medications that prolong the QT interval should be carefully monitored, as Gilteritinib has the potential to affect cardiac repolarization in rare cases.

Contraindications

Gilternib is contraindicated in patients with known hypersensitivity to Gilteritinib or any component of the formulation. Use with caution in patients with preexisting QT prolongation, significant hepatic dysfunction, or those with severe cardiac comorbidities.

Side Effects

Common adverse effects include fatigue, nausea, diarrhea, fever, elevated liver enzymes, and musculoskeletal pain. Less frequent but serious effects can include differentiation syndrome, QT prolongation, myelosuppression, and hepatotoxicity. Patients should be monitored regularly for signs of infection, electrolyte imbalance, and liver function abnormalities. Prompt dose adjustment or temporary discontinuation may be necessary for severe reactions.

Pregnancy & Lactation

The safety of Gilternib in pregnancy or breastfeeding has not been established. It should only be used in pregnant or lactating women if the potential benefit outweighs the potential risk to the fetus or infant. Effective contraception is recommended for both males and females during treatment and for a specified period afterward.

Precautions & Warnings

Regular monitoring of blood counts, liver function, and cardiac status is essential. Patients should be educated to report symptoms such as fever, shortness of breath, chest pain, or palpitations. Dose modification may be required for toxicity management.

Therapeutic Class

FLT3 Tyrosine Kinase Inhibitor

Storage Conditions

Store in a cool, dry place below 30°C, protected from light and moisture. Keep out of reach of children.